Cumberland Pharmaceuticals Inc. Stock News

-  New Dosing Regimen Simplifies Administration  - NASHVILLE, Tenn. , Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon.

–        New Real World Study of 150,000 Patients Favors Caldolor over ketorolac   – –        DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations   – NASHVILLE, Tenn. , Nov. 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9....

NASHVILLE, Tenn. , Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

–        Real World Study Compared Over 150,000 Adult & Pediatric Patients – –        Caldolor Associated with Fewer Adverse Drug Reactions – –        Caldolor also Improved Healthcare Utilization – NASHVILLE, Tenn. , Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (Nasdaq: CPIX) today announced the publication of new real-world outcomes research demonst...

NASHVILLE, Tenn. , Oct. 31, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financial results and provide a company update after the market closes on Thursday, Nov. 7, 2024.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q2 2024 Results Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon.

NASHVILLE, Tenn. , Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024.